vs

Side-by-side financial comparison of CROWN CRAFTS INC (CRWS) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

CROWN CRAFTS INC is the larger business by last-quarter revenue ($20.7M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). CROWN CRAFTS INC runs the higher net margin — 7.3% vs -177.4%, a 184.7% gap on every dollar of revenue. On growth, CROWN CRAFTS INC posted the faster year-over-year revenue change (-11.3% vs -11.5%). CROWN CRAFTS INC produced more free cash flow last quarter ($2.3M vs $-23.1M). Over the past eight quarters, CROWN CRAFTS INC's revenue compounded faster (-6.7% CAGR vs -12.2%).

Crown Crafts is a publicly held American company headquartered in Gonzales, Louisiana. The company designs, markets and distributes infant, toddler and juvenile consumer products. Its stock is traded on the NASDAQ Capital Market under the ticker symbol "CRWS".

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CRWS vs LAB — Head-to-Head

Bigger by revenue
CRWS
CRWS
1.1× larger
CRWS
$20.7M
$19.6M
LAB
Growing faster (revenue YoY)
CRWS
CRWS
+0.2% gap
CRWS
-11.3%
-11.5%
LAB
Higher net margin
CRWS
CRWS
184.7% more per $
CRWS
7.3%
-177.4%
LAB
More free cash flow
CRWS
CRWS
$25.4M more FCF
CRWS
$2.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CRWS
CRWS
Annualised
CRWS
-6.7%
-12.2%
LAB

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
CRWS
CRWS
LAB
LAB
Revenue
$20.7M
$19.6M
Net Profit
$1.5M
$-34.7M
Gross Margin
23.5%
48.5%
Operating Margin
-0.5%
-168.5%
Net Margin
7.3%
-177.4%
Revenue YoY
-11.3%
-11.5%
Net Profit YoY
69.1%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRWS
CRWS
LAB
LAB
Q4 25
$20.7M
Q3 25
$23.7M
$19.6M
Q2 25
$15.5M
$21.8M
Q1 25
$23.2M
$40.8M
Q4 24
$23.4M
Q3 24
$24.5M
$22.1M
Q2 24
$16.2M
$22.5M
Q1 24
$45.5M
Net Profit
CRWS
CRWS
LAB
LAB
Q4 25
$1.5M
Q3 25
$1.2M
$-34.7M
Q2 25
$-1.1M
$-33.5M
Q1 25
$-10.8M
$-26.0M
Q4 24
$893.0K
Q3 24
$860.0K
$-26.9M
Q2 24
$-322.0K
$-45.7M
Q1 24
$-32.2M
Gross Margin
CRWS
CRWS
LAB
LAB
Q4 25
23.5%
Q3 25
27.7%
48.5%
Q2 25
22.7%
48.8%
Q1 25
18.3%
48.4%
Q4 24
26.1%
Q3 24
28.4%
54.9%
Q2 24
24.5%
46.1%
Q1 24
53.1%
Operating Margin
CRWS
CRWS
LAB
LAB
Q4 25
-0.5%
Q3 25
7.9%
-168.5%
Q2 25
-7.7%
-118.1%
Q1 25
-60.7%
-80.8%
Q4 24
7.3%
Q3 24
6.2%
-120.9%
Q2 24
-1.8%
-134.5%
Q1 24
-132.2%
Net Margin
CRWS
CRWS
LAB
LAB
Q4 25
7.3%
Q3 25
4.9%
-177.4%
Q2 25
-7.1%
-153.7%
Q1 25
-46.4%
-63.8%
Q4 24
3.8%
Q3 24
3.5%
-122.0%
Q2 24
-2.0%
-203.3%
Q1 24
-70.6%
EPS (diluted)
CRWS
CRWS
LAB
LAB
Q4 25
Q3 25
$-0.09
Q2 25
$-0.10
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.03
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRWS
CRWS
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$2.4M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$39.2M
$399.7M
Total Assets
$76.1M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRWS
CRWS
LAB
LAB
Q4 25
$2.4M
Q3 25
$810.0K
$129.4M
Q2 25
$227.0K
$158.6M
Q1 25
$521.0K
$150.9M
Q4 24
$1.1M
Q3 24
$2.0M
$210.6M
Q2 24
$1.1M
$269.8M
Q1 24
$287.1M
Total Debt
CRWS
CRWS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CRWS
CRWS
LAB
LAB
Q4 25
$39.2M
Q3 25
$38.4M
$399.7M
Q2 25
$37.9M
$424.5M
Q1 25
$39.6M
$454.6M
Q4 24
$51.1M
Q3 24
$50.8M
$489.3M
Q2 24
$50.7M
$510.3M
Q1 24
$577.3M
Total Assets
CRWS
CRWS
LAB
LAB
Q4 25
$76.1M
Q3 25
$77.5M
$539.6M
Q2 25
$76.0M
$557.0M
Q1 25
$81.2M
$579.6M
Q4 24
$98.7M
Q3 24
$99.3M
$681.5M
Q2 24
$76.4M
$708.7M
Q1 24
$777.7M
Debt / Equity
CRWS
CRWS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRWS
CRWS
LAB
LAB
Operating Cash FlowLast quarter
$2.7M
$-22.2M
Free Cash FlowOCF − Capex
$2.3M
$-23.1M
FCF MarginFCF / Revenue
11.3%
-118.1%
Capex IntensityCapex / Revenue
1.7%
4.5%
Cash ConversionOCF / Net Profit
1.78×
TTM Free Cash FlowTrailing 4 quarters
$9.1M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRWS
CRWS
LAB
LAB
Q4 25
$2.7M
Q3 25
$-845.0K
$-22.2M
Q2 25
$5.2M
$-20.7M
Q1 25
$2.8M
$-30.3M
Q4 24
$-36.0K
Q3 24
$-983.0K
$-27.9M
Q2 24
$8.0M
$-39.0M
Q1 24
$-62.5M
Free Cash Flow
CRWS
CRWS
LAB
LAB
Q4 25
$2.3M
Q3 25
$-1.0M
$-23.1M
Q2 25
$5.2M
$-22.6M
Q1 25
$2.6M
$-35.3M
Q4 24
$-220.0K
Q3 24
$-1.2M
$-30.1M
Q2 24
$7.7M
$-41.0M
Q1 24
$-63.3M
FCF Margin
CRWS
CRWS
LAB
LAB
Q4 25
11.3%
Q3 25
-4.3%
-118.1%
Q2 25
33.4%
-103.6%
Q1 25
11.3%
-86.6%
Q4 24
-0.9%
Q3 24
-4.8%
-136.4%
Q2 24
47.7%
-182.2%
Q1 24
-138.9%
Capex Intensity
CRWS
CRWS
LAB
LAB
Q4 25
1.7%
Q3 25
0.7%
4.5%
Q2 25
0.6%
8.7%
Q1 25
0.9%
12.4%
Q4 24
0.8%
Q3 24
0.8%
10.2%
Q2 24
1.8%
8.6%
Q1 24
1.7%
Cash Conversion
CRWS
CRWS
LAB
LAB
Q4 25
1.78×
Q3 25
-0.73×
Q2 25
Q1 25
Q4 24
-0.04×
Q3 24
-1.14×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRWS
CRWS

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons